NX1907

NX1907 is a preclinical-stage small molecule drug candidate being developed by NEXTGEN Bioscience for the treatment of idiopathic pulmonary fibrosis (IPF). It functions as a dual inhibitor of macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT, also known as MIF-2). These two cytokines are structurally related and share the CD74 receptor, playing critical roles in promoting the inflammatory and fibrotic processes that characterize IPF. By simultaneously inhibiting both MIF and D-DT, NX1907 aims to provide superior anti-fibrotic activity compared to single-target inhibitors, potentially offering a new therapeutic approach to slow disease progression and improve lung function in patients with fibrotic lung diseases.